Stock Upgrades Today

 TopRated
 
  TopRated
 
Follow  Message
 
 
 
TopRatedStocks uncovering top-rated companies. Providing quick insights and recommendations, they help investors discover high-potential stocks based on robust metrics.
 

•  22 Jan 2026
 

•   ALB  
   
  +0.15%
•   ALMS  
   
  +0.11%
•   AMZE  
   
  +1.49%
•   ANF  
   
  +0.20%
•   AQST  
   
  +0.31%

$ALB Truist Securities upgraded Albemarle from Hold to Buy today, signaling confidence in the specialty chemicals leader despite a modest analyst price forecast suggesting limited downside. The stock drew higher-than-average trading volume, reflecting renewed interest from traders seeking exposure to lithium and advanced materials.

$ALMS Chardan Capital initiated coverage of Alumis with a Buy recommendation, highlighting compelling upside potential. Shares traded slightly lower, but the long-term growth story is catching attention as traders evaluate the industrial specialty products and expansion prospects.

$AMZE Ladenburg Thalmann started coverage of Amaze Holdings with a Buy rating, sending shares sharply higher on a surge in trading activity. The significant movement indicates heightened trader interest and optimism about the niche opportunities.

$ANF Citigroup upgraded Abercrombie & Fitch from Neutral to Buy, citing strong upside potential. Shares pulled back slightly, creating a potential entry point for traders who view the brand strategic repositioning and consumer engagement as catalysts for further growth. Lighter volume suggests patient accumulation ahead of potential retail-driven strength.

$AQST Crinetics Pharmaceuticals continues to draw attention after a positive mention by Jim Cramer and a Goldman Sachs Buy rating. Despite a small pullback, traders may see the recent volatility as an opportunity to position in this emerging biotech with high growth potential. Volume remains strong, highlighting speculative but promising upside in niche pharmaceutical plays.

$BMY UBS upgraded Bristol-Myers Squibb to Buy, reflecting renewed momentum in the biotech and pharma space. Analysts point to portfolio strength and dividend yield as key factors, making it appealing for both growth and income-focused traders. High trading volume indicates steady institutional participation.

$CFG Citizens Financial Group saw forecasts raised following strong quarterly earnings that beat expectations. Investors are focused on the execution on growth initiatives and improving net interest margins, making it a compelling play for traders looking for stability in financials amid a rising rate environment.

$CYH Community Health Systems remains a risky but supported buy. Analysts maintain optimism for selective healthcare plays even in a turbulent operating environment, positioning the stock as a contrarian option for traders with a higher risk appetite seeking potential recovery.

$DDOG Datadog rose after Stifel upgraded the stock, citing attractive risk-reward in the cloud monitoring space. Surging trading volume confirms strong trader interest. As enterprises increasingly adopt AI and cloud solutions, Datadog recurring revenue model and growth trajectory make it a near-term favorite for tech-focused traders.

$EMN Eastman Chemical received a Buy rating with a raised target. Analysts highlight resilient demand in the specialty chemicals space and operational efficiency, signaling a steady near-term opportunity for investors looking at industrial plays with moderate upside.

$GENI Genius Sports saw an upgrade to Overweight, citing expanding media and advertising opportunities. Shares traded lower, offering a potential entry point for traders eyeing mid-cap growth in sports technology and data monetization.

$GOOG Google received an upgrade based on a bullish outlook for AI and cloud computing. Investor confidence is supported by the diversified revenue streams and AI leadership, appealing to traders seeking sustainable growth in large-cap tech.

$LNT Alliant Energy upgraded from Underweight to Equal-Weight, highlighting relative stability in regulated utilities. Traders may see the stock as a conservative play with steady dividend income amid broader market uncertainty.

$MA Mastercard was lifted to Buy, reflecting growing optimism in payments infrastructure as consumer spending trends normalize. Steady trading volume indicates ongoing investor interest, making it a strong contender for a balanced growth portfolio.

$MSFT Microsoft remains firmly in the buy camp. The AI investments and cloud dominance continue to position it as a market leader, appealing to traders and investors seeking both near-term catalysts and long-term stability.

$NVDA NVIDIA had its price target raised while maintaining a Buy rating. Intense trading activity reflects strong interest in AI chipmakers. NVIDIA leadership in AI and GPU markets makes it a compelling near-term growth story for tech-focused traders.

$OVV Ovintiv remains attractive for dividend-focused energy investors, offering a stable high-quality portfolio and modest upside. Steady trading volume indicates accumulation by value-oriented traders.

$PGNY Progyny upgraded to Buy with a higher price target. The move reflects improving earnings visibility in fertility solutions. Investors may view the pullback as a chance to enter a mid-cap growth play with structural tailwinds in healthcare services.

$UNH UnitedHealth Group remains a Buy after reaffirmation by analysts. With Medicare Advantage trends and consistent earnings growth, the stock offers both stability and moderate near-term upside for healthcare investors.

$UPWK Upwork surged after a Buy upgrade tied to new AI offerings. Elevated trading volume highlights its position as a high-momentum tech stock with short-term upside potential.

$VRTX Vertex Pharma upgraded at RBC Capital Markets, highlighting 2026 upside potential driven by pipeline success, offering a compelling biotech opportunity for long-term traders.

View All Headlines